Metraipolis › archive › dc_f4e85b6aaf83

Real-World Outcomes of First-Line Palbociclib Plus Endocrine Therapy for HR+/HER2- Metastatic Breast Cancer in Japan: A Single-Center Retrospective Study — Europe PMC PMID:41502524

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41502524
DOI
10.32604/or.2025.073891
License (as archived)
solo-consultazione
Archived
2026-11-07T07:47:49.463Z
SHA-256 of the archived text
ce08069f98159381233e8565a82d73e061599cbe90df8c1c0cc985815d582a4f
Stable URL of this page
https://metraipolis.com/documento/dc_f4e85b6aaf83

How to cite

Real-World Outcomes of First-Line Palbociclib Plus Endocrine Therapy for HR+/HER2- Metastatic Breast Cancer in Japan: A Single-Center Retrospective Study — Europe PMC PMID:41502524 — Europe PMC (en), https://europepmc.org/article/MED/41502524 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f4e85b6aaf83 (Metraipolis archive dc_f4e85b6aaf83, sha256 ce08069f98159381233e8565a82d73e061599cbe90df8c1c0cc985815d582a4f)
BibTeX
@misc{dcf4e85b6aaf83,
  title = {Real-World Outcomes of First-Line Palbociclib Plus Endocrine Therapy for HR+/HER2- Metastatic Breast Cancer in Japan: A Single-Center Retrospective Study — Europe PMC PMID:41502524},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41502524},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f4e85b6aaf83; sha256 ce08069f98159381233e8565a82d73e061599cbe90df8c1c0cc985815d582a4f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41502524. Agents can read the archived copy with the MCP tool read_document.